BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Launches Payments Intelligence and IXONav, an AI Payments Assistant Built to Unlock Real-Time Insights Across the Payments Journey2.6.2026 06:00:00 CEST | Press release
Company's intelligence layer combines AI-driven analytics with anomaly detection to improve merchant payments optimization, performance and revenue outcomes LEHI, UT / ACCESS Newswire / June 2, 2026 / IXOPAY, the performance layer powering global payments for the agentic era, today announced IXOPAY Payments Intelligence, a unified control center that transforms fragmented payment data into real-time, actionable insights. The company also launched IXONav, a new AI agentic navigator built to unlock key insights at every step in the payments journey. By combining AI-driven analytics, anomaly detection and LLM agents, the platform helps merchants uncover optimization opportunities, improve routing performance, increase authorization rates and reduce per-transaction costs. IXOPAY's no-code payments platform unifies payment orchestration, tokenization, and intelligence, and provides merchants with a configurable infrastructure to optimize their payments performance. The IXOPAY Payments Intel
Clean Air Metals Files Audited Annual Financial Statements for the Year Ended January 31, 20262.6.2026 03:00:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 1, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its audited consolidated financial statements and management's discussion and analysis for the year ended January 31, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at January 31, 2026 of $36,226,670 Total cash as at January 31, 2026 of $1,133,766 Working capital deficiency as at January 31, 2026 of $2,281,241 Shareholder's equity as at January 31, 2026 of $32,604,804 During the year ended January 31, 2026, the Company incurred $1,190,489 in cost for exploration activities at the TBN project. Early in the year, the Company's management team executed a successful drill program at the Current Deposit to delineate larger ballroom structures. This was followed up by a significant undertaking at the Escape Deposit down plunge, to reassess past MT data and refine drilling targets in
Graid Technology Launches VROC(TM) by Graid Technology with 24-Month Roadmap and Tier 1 OEM Support2.6.2026 02:00:00 CEST | Press release
VROC™ by Graid Technology brings active development, Intel® Xeon® 6 platform support, and no-cost upgrades to an established CPU-based NVMe RAID foundation. SUNNYVALE, CA / ACCESS Newswire / June 1, 2026 / Graid Technology, creator of SupremeRAID™ and global steward of Intel® VROC, today announced VROC™ by Graid Technology, a rebranded and actively developed platform with a 24-month roadmap delivering new features, expanded platform support, and long-term investment for existing and future customers. Intel® VROC has served as the CPU-based software RAID foundation for Intel-powered enterprise servers across Tier 1 platforms worldwide. Under Graid Technology's stewardship, the product transitions from sustained maintenance into active development with no disruption to existing deployments. The VROC™ by Graid Technology roadmap includes: Intel® Xeon® 6 platform support - including Oak Stream (Diamond Rapids) - with no-cost upgrades for existing Intel® VROC customers Hardware key eliminat
Karbon-X to Present at the Small Cap Growth Virtual Investor Conference June 4th1.6.2026 15:30:00 CEST | Press release
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com CALGARY, AB / ACCESS Newswire / June 1, 2026 / Karbon-X Corp. (OTCQB:KARX), based in Calgary, Alberta focused on global carbon markets and climate infrastructure solutions, today announced that Chad Clovis, Chief Executive Officer will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on June 4, 2026 DATE: June 4th TIME: 10:00 AM ET REGISTER HERE Available for 1x1 meetings: June 5th-9th Schedule 1x1 Meetings here. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive
Resin Solutions LLC Introduces "Stratix(TM)" Brand Architecture for Products Serving the Aerospace and Defense Applications1.6.2026 15:00:00 CEST | Press release
EXTON, PA / ACCESS Newswire / June 1, 2026 / Resin Solutions LLC, a leading provider of advanced material solutions, today announced the launch of Stratix™, a new brand identity reflecting the company's deepened strategic focus on the Aerospace and Defense sector. This new designation underscores the company's long-term commitment to supporting the unique and demanding requirements of aerospace and defense customers. By clearly bringing both its existing and in-development aerospace and defense products under the Stratix™ brand name, Resin Solutions aims enhance customer confidence, streamline product selection, and further strengthen its partnerships within the sector. The Stratix™ brand trademark will be applied to a growing portfolio of materials engineered to meet the rigorous performance, quality, and reliability expectations critical to aerospace and defense applications. Among the first products to carry the designation are Resin Solutions' flagship and highly-specified aerospac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom